Business
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n LOS ANGELES, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), today announced an additional opportunity to view a live webinar presentation ‘The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients Undergoing Cardiothoracic Surgery’ with Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine on Thursday, September 17th at 5:00 pm Eastern Standard Time. The results of the study demonstrate that the use of SofPulse® significantly decreased postoperative pain VAS (Visual Analog Scale) by 50%, decreased postoperative opioid requirements (morphine equivalent dose) by 70% and resulted in a significant decrease in Length of Stay (LOS) at the hospital by a median of 2 days. The American Reporter article, published in August 2020, stated that “Coronary artery bypass graft (CABG) surgery is the most common type of open-heart surgery, and up to 500,000 CABG surgeries are performed in the US yearly with patient hospitalization averaging one week or 7 days.” The American Reporter article continued, “It is simply too hard to ignore the overall savings to hospitals if they simply added SofPulse® as a standard of care for all CABG cases yearly.” “A two-day reduction in the median Length of Stay (LOS) for CABG surgeries equates to a daily savings of $5,714, and a cumulative average realized savings to hospitals of $11,428 for each surgery performed.” “With 500,000 cases performed yearly in the US, the potential cost savings realized by hospitals could result in overall cost savings to in-patient and hospital care of $5,714,000,000.” Endonovo CEO Alan Collier states, “We are extremely honored to have the opportunity to support Dr. Awad in presenting these significant results utilizing the FDA Cleared SofPulse® PEMF device. The economic findings, cost savings and reduction of opioid use to hospitals and patients recovering from open heart type of surgeries from the Baylor College of Medicine study are stunning. Findings showing a significant reduction in the median Length of Stay (LOS) of 2 days for open heart type of surgeries proves that SofPulse® can provide hospitals significant savings on similar inpatient surgeries requiring postoperative pain ...